<code id='8A37225B9E'></code><style id='8A37225B9E'></style>
    • <acronym id='8A37225B9E'></acronym>
      <center id='8A37225B9E'><center id='8A37225B9E'><tfoot id='8A37225B9E'></tfoot></center><abbr id='8A37225B9E'><dir id='8A37225B9E'><tfoot id='8A37225B9E'></tfoot><noframes id='8A37225B9E'>

    • <optgroup id='8A37225B9E'><strike id='8A37225B9E'><sup id='8A37225B9E'></sup></strike><code id='8A37225B9E'></code></optgroup>
        1. <b id='8A37225B9E'><label id='8A37225B9E'><select id='8A37225B9E'><dt id='8A37225B9E'><span id='8A37225B9E'></span></dt></select></label></b><u id='8A37225B9E'></u>
          <i id='8A37225B9E'><strike id='8A37225B9E'><tt id='8A37225B9E'><pre id='8A37225B9E'></pre></tt></strike></i>

          explore

          explore

          author:entertainment    Page View:59
          Humana sued the federal government Friday over a rule that claws back overpayments from it and other Medicare Advantage insurers. Adobe

          Humana sued the federal government Friday, arguing that this year’s new rule to claw back overpayments from it and other Medicare Advantage insurers violates federal law due to its “shifting justifications and erroneous legal reasoning.”

          “The [Centers for Medicare and Medicaid Services] did not even try to offer an empirical or actuarial justification for its new audit methodology, relying instead on purely legal rationales — none of which withstand scrutiny,” Humana said in the lawsuit.

          advertisement

          The health insurance industry has threatened a lawsuit over this old and contentious auditing process since last year. Humana executives specifically mentioned at this year’s J.P. Morgan Healthcare Conference that they would consider suing the government if the audit rule did not contain certain components they deemed were necessary.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          knowledge

          Moonlake's readout produced a cash windfall. Risks remain
          Moonlake's readout produced a cash windfall. Risks remain

          MollyFerguson/STATFortwodaysstartingonSunday,MoonlakeImmunotherapeuticshappilycrunchednumbersandshar

          read more
          FDA panel endorses Alnylam’s heart drug — after picking it apart
          FDA panel endorses Alnylam’s heart drug — after picking it apart

          KristofferTripplaar/SipaUSA/APAgroupofadviserstotheFoodandDrugAdministrationvotedinfavorofAlnylamPha

          read more
          Novavax promises a turnaround & Lilly roils the obesity market
          Novavax promises a turnaround & Lilly roils the obesity market

          SammyKimballforSTATCanNovavaxfinallygetitright?What’sa“triple-G”drug?AndisNovoNordisklosingground?We

          read more

          Long Covid needs a new name — and a new frame

          AdvocatesforpeoplewithlongCovidandmyalgicencephalomyelitis/chronicfatiguesyndromehostaninstallationo